Revolution Medicines Inc (Revolution Medicines) is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US
Headquarters
United States of America
Address
700 Saginaw Dr, Redwood City, California, 94063-4752
Website
www.revmed.com
Telephone
1 415 7663638
No of Employees
378
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RVMD (NASD)
Revenue (2022)
$11.6M
-67.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-75.5%
(2022 vs 2021)
Market Cap*
$5.8B
Net Profit Margin (2022)
XYZ
-436.1%
(2022 vs 2021)
* As of and is in US$
Revolution Medicines Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Medicines and Therapies |
| RMC-4630 |
| RMC-4630 (SHP2) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into an agreement with Aethon Therapeutics to create therapies for RAS-addicted cancers. |
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company acquired EQRx, a biopharmaceutical company. |
| 2020 | Stock Listings/IPO | In January, the company announced its plans to raise IPO of shares. |
Competitor Comparison
| Key Parameters | Revolution Medicines Inc | Amneal Pharmaceuticals Inc | Surface Oncology Inc | Gritstone Bio Inc | Entasis Therapeutics Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Redwood City | Bridgewater | Cambridge | Emeryville | Waltham |
| State/Province | California | New Jersey | Massachusetts | California | Massachusetts |
| No. of Employees | 378 | 7,700 | 60 | 231 | 51 |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark A. Goldsmith | Chief Executive Officer; Director; President | Executive Board | 2014 | 61 |
| Walter Reiher | Chief Information Officer | Senior Management | - | - |
| Shaoling Li | Senior Vice President - CMC and Quality | Senior Management | - | - |
| Bojena Bitman | Vice President - Quantitative Sciences | Senior Management | 2019 | - |
| Stephen Chan | Vice President - Clinical Data Management, Statistical Programming and Clinical Systems | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward